Your search for major depressive disorder returned 3 results

The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.

The FDA has approved Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer disease.

The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.